Ultragenyx Pharmaceutical
RARE
270 hedge funds and large institutions have $3.73B invested in Ultragenyx Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 99 increasing their positions, 77 reducing their positions, and 20 closing their positions.
165% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 20
87% more call options, than puts
Call options by funds: $31.5M | Put options by funds: $16.9M
29% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 77
14% more funds holding
Funds holding: 237 → 270 (+33)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.93% less ownership
Funds ownership: 98% → 97.06% (-0.93%)
3% less capital invested
Capital invested by funds: $3.85B → $3.73B (-$119M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$32M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$22.6M |
| 3 |
BNP Paribas Asset Management
Paris,
France
|
+$20M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$17.4M |
| 5 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$43M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$41.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$37.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$31M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$24.6M |
RARE Hedge Fund Activity: Q1 2024 in Review
270 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2024, worth a combined $3.73B — down 3.1% from $3.85B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new RARE positions and 20 closed out — a net gain of 33 holders — while 99 added to existing stakes and 77 trimmed.
The largest buyer was Millennium Management, adding an estimated $32M. The largest seller was Camber Capital Management, exiting entirely with an estimated $43M sold.
- 270 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2024, up from 237 in Q4 2023.
- Funds reported $3.73B of Ultragenyx Pharmaceutical stock for Q1 2024, down 3.1% quarter-over-quarter.
- 53 funds opened new Ultragenyx Pharmaceutical positions in Q1 2024 and 20 closed out, a net change of +33 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2024 was Millennium Management, an estimated $32M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2024 was Camber Capital Management, an estimated $43M sold.
Based on aggregated 13F filings for Q1 2024.